Boey (trenibotulinumtoxinE) is authorized in Canada for glabellar lines and works in hours instead of days, with effects lasting two to three weeks.

At the 2026 Aesthetic & Anti-Aging Medicine World Congress, Allergan Aesthetics unveils 21 evidence-based e-posters, emphasizing safety and efficacy in aesthetic treatments.

- Poster presentation highlights investigational neurotoxin trenibotulinumtoxinE (TrenibotE), demonstrating rapid onset and a consistently favorable safety profile across studied patient populations - Poster presentation explores mindset and characteristics of GLP-1 agonist-treated...

Allergan Aesthetics (ABBV) will present 21 evidence-based e-posters at AMWC Monaco, March 26-28, 2026, covering clinical, real-world and preclinical research. Key highlights include investigational neurotoxin trenibotulinumtoxinE with rapid improvement as early as 8 hours and short 2-3 week duration, BOTOX Cosmetic real-world satisfaction and multimodal care trends, VYC-12L/VYC-20L hyaluronic acid data with up to 6 months of benefit, HA-CaHA durability to 18 months, and CoolSculpting molecular evidence for lasting fat reduction.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the European Commission has approved Boey® (trenibotulinumtoxinE) in Europe, for the temporary

Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹ Results may be seen as early as eight hours after treatment and typically wear off within...

Phase 3 results for TrenibotulinumtoxinE show a rapid-onset profile that may shift clinical standards in aesthetic medicine.

AbbVie is hoping to extend its range of neurotoxin-based pharma and cosmetic products with a short-acting successor to its blockbuster Botox brand.

Allergan Aesthetics has shared new research on its investigational neurotoxin TrenibotulinumtoxinE at a major dermatology meeting. The presentations also examined trends among weight loss patients see...

AbbVie has taken a significant step in the aesthetics field by submitting a Biologics License Application to the U.S. Food and Drug Administration for its product trenibotulinumtoxinE (TrenibotE).

Phase 3 results for TrenibotulinumtoxinE show a rapid-onset profile that may shift clinical standards in aesthetic medicine.

Reported Thursday, Apr 23 - 4:09pm EDT (TheFly subscription required to read more.)

Reported Thursday, Apr 24 - 8:34am EDT (TheFly subscription required to read more.)

Allergan Aesthetics has received a favorable CHMP opinion for Boey®, marking a significant step towards addressing glabellar lines with this innovative treatment.

AbbVie announces receiving a Complete Response Letter from the FDA regarding TrenibotE's Biologics License Application, focusing on manufacturing processes without additional studies required.

Allergan Aesthetics presented new findings on the safety and efficacy of TrenibotulinumtoxinE at the American Academy of Dermatology Meeting 2026, showcasing significant advancements.

Allergan Aesthetics reveals cutting-edge data on facial injectables, showcasing new neurotoxin innovations and patient satisfaction at the IMCAS 2026 event in Paris.

AbbVie has submitted a Biologics License Application for TrenibotulinumtoxinE (TrenibotE), a treatment targeting glabellar lines, to the U.S. FDA, showcasing rapid efficacy.

U.S. Food and Drug Administration issues Complete Response Letter for trenibotulinumtoxinE related to manufacturing processes; no additional clinical studies are requested As the leader in neurotoxin development and manufacturing, AbbVie is well positioned to address all comments in a timely manner. NORTH CHICAGO, Ill., April 23, 2026/ PRNewswire/-- AbbVie...

Canada is the first country to approve a new botulinum neurotoxin serotype for aesthetic use Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved for the temporary improvement in the appearance of glabellar lines Boey® offers a differentiated...

- Nine e-posters presenting comprehensive Allergan Aesthetics portfolio data spanning first-in-class botulinum neurotoxin serotype E (TrenibotulinumtoxinE, "TrenibotE"), onabotulinumtoxinA, hyaluronic acid-based fillers and an innovative filler with biostimulatory properties - Pooled...